UNIS, OMED, TAXI, CNAT added to NASDAQ Active Stock Watch List at EPR


Follow this company

Companies Mentioned

NASDAQ:UNIS / NASDAQ:OMED / NASDAQ:TAXI / NASDAQ:CNAT
12/03/2013 [ACCESSWIRE]

New York, NY - (ACCESSWIRE) - 12/03/2013 - Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding Unilife Corporation (NASDAQ:UNIS), OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), Medallion Financial Corp. (NASDAQ:TAXI), and Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) 

Unilife Corporation (NASDAQ:UNIS) a company that designs, develops, manufactures, and commercializes injectable drug delivery systems in the United States and internationally is currently up (+22.41%) on 2,969,777 shares traded after Unilife Announced Clinical Supply Agreement for Delivery of a Novel Drug. Unilife Corporation (NASDAQ:UNIS) is currently up (+175%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll. 

To find out what other Investors are saying about Unilife Corporation (NASDAQ:UNIS)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=UNIS&SubId=AW 

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biotechnology company that focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem Cells is currently up (+77.64%) on 1,411,122 shares traded after ONCOMED PHARMACEUTICALS INC Filed SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) is currently up (+98.84%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll. 

To find out what other Investors are saying about OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=OMED&SubId=AW 

Medallion Financial Corp. (NASDAQ:TAXI) through its subsidiaries, operates as a specialty finance company in the United States is currently down (-8.67%) on 1,100,077 shares traded after Medallion Financial Corp. announced underwritten public offering of 2,900,000 shares of its common stock at a price of $16.40 per share. Medallion Financial Corp. (NASDAQ:TAXI) is currently down (-10.42%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll. 

To find out what other Investors are saying about Medallion Financial Corp. (NASDAQ:TAXI)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=TAXI&SubId=AW 

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) a biotechnology company that focuses on the development and commercialization of medicines to treat liver diseases in the United States is currently up (+22.80%) on 668,260 shares traded after CONATUS PHARMACEUTICALS INC Filed SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) is currently up (+40.55%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll. 

To find out what other Investors are saying about Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=CNAT&SubId=AW 

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.equityprofilereport.com/

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com  
COMMENTS

Leave a comment...
 * 

Your Name
 *